DifGen Pharmaceuticals LLC Receives USFDA Approval for Fluorometholone Ophthalmic Suspension, 0.1% - Expanding Its Complex Generic Portfolio
PR Newswire —
MIRAMAR, Fla., Feb. 12, 2026 /PRNewswire/ -- DifGen Pharmaceuticals, a leading US based generic pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (USFDA) for its Fluorometholone Ophthalmic Suspension, 0.1% - a complex generic...